Result: Risk Minimisation Materials for medicines starting with the letter C

Cablivi

Sanofi Genzyme

Cablivi 10 mg powder and solvent for solution for injection – Patient Card - Risk Minimisation Information for Patients

Cablivi is subject to additional monitoring. This will allow quick identification of new safety information. If you notice any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Caprelsa

Sanofi Genzyme

Caprelsa ( Vandetanib) – Patient Card - Risk Minimisation Information for Patients

This medicine is subject to additional monitoring. This will allow quick identication of new safety information. You can help by reporting any side effects you may get. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected] In the UK see www.mhra.gov.uk/yellowcard for how to report side effects

Caprelsa (Vandetanib) - Patient Guide - Risk Minimisation Information for Patients

The guide should be provided to patients prior to treatment by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring including your doctors contact details and an overview of treatment monitoring For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Caprelsa (Vandetanib) - Risk minimisation HCP Guide

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

Carbimazole

ADVANZ Pharma

Carbimazole or thiamazole* (synonym: methimazole)-containing products: risk of acute pancreatitis and strengthened advice on contraception

Carbimazole or thiamazole* (synonym: methimazole)-containing products: (1) risk of acute pancreatitis and (2) strengthened advice on contraception

For Healthcare Professionals

Cellcept

Roche Products Limited

CellCept: Guide for Healthcare Professionals

This material is provided by Roche Products Ltd and forms part of the licence requirement. Please ensure that you are familiar with this material as it contains important safety information

For Healthcare Professionals

CellCept: Guide for Patients

This material is provided by Roche Products Ltd as a licence requirement. Please ensure that you are familiar with this material as it contains important safety information.

Ceptava

Sandoz Limited

Healthcare Provider Guide

This guide details the risk of teratogenicity.

For Healthcare Professionals

Patient Guide

This guide details the risks of miscarriage and birth defects.

Cerdelga

Sanofi Genzyme

CERDELGA (eliglustat) Prescriber Guide

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

CERDELGA (eliglustat) Patient Alert card

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

Cerezyme

Sanofi Genzyme

Cerezyme (imiglucerase) - Home Infusion HCP Manual - Risk Minimisation Information for Healthcare Professionals

The objective of this document is to provide guidance to healthcare professionals for the management of patients receiving Cerezyme (imiglucerase) at home. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

Cerezyme (imiglucerase) - Home Infusion Patient Manual - Risk Minimisation Information for Patients

The objective of this document is to provide patients with guidance on how to receive Cerezyme (imiglucerase) at home. It is the responsibility of the treating physician to supply this material to patients only if the treating physician decides that the patient is eligible for home infusion treatment.

Cimzia

UCB Pharma Limited

Cimzia Patient Alert card

This alert card contains important safety information that patients need to be aware of before they are given CIMZIA and during treatment with CIMZIA.

Cinryze

Shire Pharmaceuticals Limited

Cinryze - Risk Management Plan Letter

Letter sent to HCPs informing them of the updated educational materials and website for the reconstitution and administraiton of Cinryze

For Healthcare Professionals

Cinryze Patient Diary

This Patient Diary is intended for patients to use to record the date, lot numbers, and reason for injection each time they inject Cinryze (C1 esterase inhibitor [human]) so that they can share this information with their treating physician at their next visit.

Cinryze Reconstitution and Administration Instructions for Healthcare Professionals

This Healthcare Professional Guide provides instruction on the procedures for the reconstitution and administration of Cinryze (C1 inhibitor [human]).

For Healthcare Professionals

Instructions for Patients and Caregivers on the Preparation and Administration of Cinryze

This Guide is intended for Patients and Caregivers to provide instruction on the preparation and administration of Cinryze

Co-cyprindiol

Morningside Healthcare Ltd

Checklist for Prescribers - Teragezza

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations. Cyproterone acetate and ethinylestradiol tablet are used for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age.

For Healthcare Professionals

Important Information for Women - Teragezza

The review recommended that all women should understand: the small risk of blood clots with combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; and when you need to tell a healthcare professional that you are using a combined hormonal contraceptive. Although the risk is small, blood clots can be serious. This information will help you minimise your risk.

Risk of Blood Clot - Teregezza

Important Information for women about the risk of blood clots whilst on this product. What signs and symptoms to look out for.

Fannin UK/Kent Pharma UK Limited

Co-Cyprindiol Patient Card UK

Co-Cyprindiol Patient Card UK

Co-Cyprindiol Prescriber Checklist UK

Co-Cyprindiol Prescriber Checklist UK

For Healthcare Professionals

Colobreathe

Teva UK Limited

Colistimethate Sodium - (Colobreathe) HCP User Guide

In this booklet, you will find detailed information on how to load the Colobreathe Turbospin inhaler, patients should inhale the medicine and inspect and clean the device.

For Healthcare Professionals

Colistimethate Sodium - (Colobreathe) Patient User Guide

In this booklet, you will find detailed information on how to load the Colobreathe Turbospin inhaler, how to inhale the medicine and inspect and clean the device.

Colobreathe (colistimethate sodium) Patient Card with QRD Code

Patient Card with QRD Code - To access the instructional video, please scan the QR code with a smartphone/device.

Concerta

Janssen-Cilag Ltd

Physician's guide to prescribing website

Website to host materials for physicians to support appropriate prescribing of methylphenidate

For Healthcare Professionals

cynril

Fontus Health Ltd

Cynril Patient Diary

This Patient Diary is designed to help you monitor your experience of BTcP and your use of Cynril. It will give you and your doctor a valuable insight into your progress and ensure you are receiving the correct level of treatment.

Cynril Patient Guide

Patient Guide For Cynril (fentanyl citrate) Lozenges

Cynril Prescription Guide for HCP

The prescription guide is designed to provide information around the use of Cynril (fentanyl citrate) lozenges for Healthcare Professionals (HCPs). More specifically, identifying appropriate patients and correctly prescribing Cynril to minimise the risk of misuse/pharmacodependence, abuse, medication errors, drug diversion, accidental exposure, overdose, off-label use, respiratory depression and local tolerability (dental decay) in patients not receiving opioid background therapy.

For Healthcare Professionals